PubMed Health⌕ Search

PubMed · 12366759

Making risk statements stick.

Abstract

Estimates of risk associated with blood transfusion are reported from a variety of sources using different numerical constructs. These data must be judged for validity and generalizability to facilitate decisions for interventions and to estimate potential benefits of interventions. Risk estimates reported in consistent terms, such as occurrences per million units transfused, will assist in comparisons of risks and the expected effect observed at the practitioner level. Use of the estimated number needed to treat puts the effect of an intervention in perspective for the individual practitioner and for national health authorities. We re-evaluated data reported from several recent studies of transfusion risk to highlight this approach. In the USA, the number needed to treat estimated to prevent one HIV transmission is 4.3 million (mini-pool NAT); to prevent one death from bacterial sepsis is 21 thousand (conversion to single donor platelets), and 16 thousand (bacterial screening of platelet concentrates). As interventions are continuing to drive infectious disease transmission rates lower and lower, expressing residual risk as the number needed to treat demonstrates that further improvements in safety are unlikely to be recognized at the local level even though the overall impact at the national level is significant.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L J Dumont, J P AuBuchon. 2002. Making risk statements stick.. https://doi.org/10.1046/j.1423-0410.2002.00233.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Hemolytic activity of new linear surfactin analogs in relation to their physico-chemical properties.

New linear analogs of surfactin have been synthesized. Their physico-chemical parameters were determined. The results indicate that these linear products show surface activities although they are lowered compared to those of cyclic compounds. The hemolytic activities have also been assayed. In contrast with cyclic surfactins, no significant hemolysis occurs for the linear products in the range of concentrations tested. Moreover, a protective effect against Triton X-100 induced hemolysis has been highlighted for linear surfactins. The concentration at which this protective effect happens is correlated directly to the CMC, and inversely to the acyl chain length of the product. In a hypotonic medium, analogs having a long acyl chain tend to increase the hemolysis, meanwhile the product with the shortest chain tends to decrease it.

Hemolysis↗